《瑞银窝轮》平保追落後、平医破顶 留意CALL平保24535、好医生26092
上周尾段在多重利好消息包括疫症有机会出现有效药物及美国设动重启经济指引出现，刺激港股突破，恒指再试24600点的阻力，但周末前获利回吐压力颇大，尤其2大重磅股腾讯(0700)已累积较大升幅，而汇丰(0005)则受其基本因素，都限制了恒指的升幅。但反观今次恒指的反弹浪，以往的强股平保(2318)反而非常落後，3月底至上周中段主要在70港元至75港元横行，期间恒指由23000点升至24600点。上周五(17日)恒指高位回落期间，平保反而突破横行区，挑战79港元位置。若後市港股要上试25000点关口，落後的内险板块或有机会发力，投资者且留意平保能否挑战80港元的心理关口。如投资者看好平安，可留意中国平安认购24535，行使价84.53港元，20年6月到期，有效杠杆约19倍。
同系的平安好医生(1833)则非常强劲，股价屡创新高，上周五更曾突破百元关创101.1港元的上市高位。经过疫情後，在线概念成为市场焦点，在线医疗的龙头平安好医生更成为宠儿，投资者如看好好医生在百元关整固升势後，有机会再破顶的话，可留意CALL轮26092，行使价100.98港元，20年8月到期，有效杠杆约4倍。
更多窝轮牛熊资讯：瑞银证网站: www.ubs.com/hkwarrants
窝证教学及市况焦点短片:
https://www.youtube.com/channel/UCKw86qy4eBAInmd52MND45Q?view_as=subscriber
周国威
董事
瑞银亚洲股票衍生产品销售部
本产品并无抵押品。 如发行人无力偿债或违约,投资者可能无法收回部份或全部应收款项。笔者为UBS AG的代表(作为证监会持牌人)，并未持有相关上市公司的任何财务权益。本资料由瑞银刊发，其并不构成买卖建议、邀请、要约或游说。结构性产品价格可急升或急跌，投资者可能会蒙受全盘损失。过往表现并不反映将来表现。牛熊证备强制赎回机制而可能被提早终止，届时 (i) N类牛熊证投资者将不获发任何金额;而(ii) R类牛熊证之剩余价值可能为零。投资前应了解有关风险，并谘询专业顾问及查阅有关上市文件。UBS Securities Hong Kong Limited为结构性产品之流通量提供者，亦可能是唯一报价者或市场参与者。(C) UBS 2020。版权所有。~
重要声明:
以上资讯由第三方提供，AASTOCKS.com Limited对於任何包含於、经由、连结、下载或从任何与本网站有关服务所获得之资讯、内容或广告，不声明或保证其内容之正确性或可靠性。对於您透过本网站上之广告、资讯或要约而展示、购买或取得之任何产品、资讯资料，本公司亦不负品质保证之责任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
